Lutein: The supplement industry's most successful clinical trial outcome is a carotenoid

The AREDS2 study (Age-Related Eye Disease Study 2) is one of the largest, most rigorous supplement trials ever conducted (4,203 participants, 5-year follow-up). It established that lutein/zeaxanthin was safer and equally effective as beta-carotene for AMD prevention. AREDS2 changed clinical practice worldwide. Lutein's commercial success is built on a single trial with a level of rigor most pharma drugs would envy.Publications of interest:https://pubmed.ncbi.nlm.nih.gov/23644932/https://pubmed.ncbi.nlm.nih.gov/24310343/https://pubmed.ncbi.nlm.nih.gov/35653117/